A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
Launched by BRISTOL-MYERS SQUIBB · Nov 14, 2006
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males and Females (not nursing or not pregnant)
- • 18-75 years of age
- • Diagnosis of moderate to severe psoriasis for at least six months at the time of screening
- • Subjects will require wash-out of certain therapies for the treatment of psoriasis but will be allowed to continue on certain topical therapies
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Malvern, Victoria, Australia
St. John's, Newfoundland And Labrador, Canada
St Leonard, Quebec, Canada
Monterrey, Nuevo Leon, Mexico
Waterloo, Ontario, Canada
Kogarah, New South Wales, Australia
Greenslopes, Queensland, Australia
North Adelaide, South Australia, Australia
Carlton, Victoria, Australia
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Surrey, British Columbia, Canada
Winnipeg, Manitoba, Canada
Halifax, Nova Scotia, Canada
Oakville, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Quebec, , Canada
Mexico, Aguascalientes, Mexico
Df, Distrito Federal, Mexico
Zapopan, Jalisco, Mexico
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials